This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies.

中文翻译：

---

卵巢癌药物市场

本文讨论了最近批准的聚ADP核糖聚合酶（PARP）抑制剂对卵巢癌药物市场以及潜在的未来治疗方法（如免疫疗法）的影响。